Literature DB >> 18266223

Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma.

Kenneth G Lucas1, Cindy Schwartz, Joel Kaplan.   

Abstract

Ewing sarcoma (ES) can express tumor antigens which can be recognized by T cells, making allogeneic stem cell transplant (SCT) a potential option for those patients with refractory disease. A 6-year old with multifocal ES developed a recurrence of pulmonary metastases and underwent an allogeneic bone marrow transplant from her human leukocyte antigen (HLA) 10/10 matched mother. During a taper of her immunosuppression, she developed grade 1 skin and oral graft versus host disease (GVHD). CT scans performed 9 months post-transplant revealed a marked decrease in the size of her pulmonary lesions compared to scans 2 months post-transplant. This case highlights the possibility of treating patients with refractory metastatic ES with allogeneic SCT. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18266223     DOI: 10.1002/pbc.21503

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN: 1545-5009            Impact factor:   3.167


  11 in total

1.  Transgenic antigen-specific, HLA-A*02:01-allo-restricted cytotoxic T cells recognize tumor-associated target antigen STEAP1 with high specificity.

Authors:  David Schirmer; Thomas G P Grünewald; Richard Klar; Oxana Schmidt; Dirk Wohlleber; Rebeca Alba Rubío; Wolfgang Uckert; Uwe Thiel; Felix Bohne; Dirk H Busch; Angela M Krackhardt; Stefan Burdach; Günther H S Richter
Journal:  Oncoimmunology       Date:  2016-04-25       Impact factor: 8.110

2.  Reduced-intensity allogeneic stem cell transplantation in children and young adults with ultrahigh-risk pediatric sarcomas.

Authors:  Kristin Baird; Terry J Fry; Seth M Steinberg; Michael R Bishop; Daniel H Fowler; Cynthia P Delbrook; Jennifer L Humphrey; Alison Rager; Kelly Richards; Alan S Wayne; Crystal L Mackall
Journal:  Biol Blood Marrow Transplant       Date:  2011-09-05       Impact factor: 5.742

3.  Successful allogeneic hematopoietic cell engraftment after a minimal conditioning regimen in children with relapsed or refractory solid tumors.

Authors:  David R Shook; Brandon M Triplett; Ashok Srinivasan; Christine Hartford; Mari H Dallas; Asha Pillai; Joseph Laver; Wing Leung
Journal:  Biol Blood Marrow Transplant       Date:  2012-10-09       Impact factor: 5.742

4.  Current therapeutic approaches in metastatic and recurrent ewing sarcoma.

Authors:  Michael Huang; Kenneth Lucas
Journal:  Sarcoma       Date:  2010-12-01

5.  Unusual sites of extraskeletal metastases of Ewing sarcoma after allogeneic hematopoietic stem cell transplantation.

Authors:  Christian M Capitini; Joanne Derdak; Marybeth S Hughes; Cynthia P Love; Kristin Baird; Crystal L Mackall; Terry J Fry
Journal:  J Pediatr Hematol Oncol       Date:  2009-02       Impact factor: 1.289

6.  Specific recognition and inhibition of Ewing tumour growth by antigen-specific allo-restricted cytotoxic T cells.

Authors:  U Thiel; S Pirson; C Müller-Spahn; H Conrad; D H Busch; H Bernhard; S Burdach; G H S Richter
Journal:  Br J Cancer       Date:  2011-03-15       Impact factor: 7.640

7.  Bone marrow involvement identifies a subgroup of advanced Ewing sarcoma patients with fatal outcome irrespective of therapy in contrast to curable patients with multiple bone metastases but unaffected marrow.

Authors:  Uwe Thiel; Angela Wawer; Irene von Luettichau; Hans-Ulrich Bender; Franziska Blaeschke; Thomas G P Grunewald; Marc Steinborn; Barbara Röper; Halvard Bonig; Thomas Klingebiel; Peter Bader; Ewa Koscielniak; Michael Paulussen; Uta Dirksen; Heribert Juergens; Hans-Jochem Kolb; Stefan E G Burdach
Journal:  Oncotarget       Date:  2016-10-25

8.  Pappalysin-1 T cell receptor transgenic allo-restricted T cells kill Ewing sarcoma in vitro and in vivo.

Authors:  Andreas Kirschner; Melanie Thiede; Thomas G P Grünewald; Rebeca Alba Rubio; Günther H S Richter; Thomas Kirchner; Dirk H Busch; Stefan Burdach; Uwe Thiel
Journal:  Oncoimmunology       Date:  2017-01-17       Impact factor: 8.110

Review 9.  Natural Killer Cells: Development, Maturation, and Clinical Utilization.

Authors:  Alex M Abel; Chao Yang; Monica S Thakar; Subramaniam Malarkannan
Journal:  Front Immunol       Date:  2018-08-13       Impact factor: 7.561

10.  Human HLA-A*02:01/CHM1+ allo-restricted T cell receptor transgenic CD8+ T cells specifically inhibit Ewing sarcoma growth in vitro and in vivo.

Authors:  Franziska Blaeschke; Uwe Thiel; Andreas Kirschner; Melanie Thiede; Rebeca Alba Rubio; David Schirmer; Thomas Kirchner; Sabine Mall; Richard Klar; Stanley Riddell; Dirk H Busch; Angela Krackhardt; Thomas G P Grunewald; Stefan Burdach
Journal:  Oncotarget       Date:  2016-07-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.